<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.5.7269.28134 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 1/10/2020 9:01:36 PM -->
      <!-- iXBRL Library version: 1.0.7269.28141 -->
      <!-- iXBRL Service Job ID: 17dea44a-0fd7-4aa2-bdc6-fa92446acd97 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:edit="http://www.editasmedicine.com/20200109" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" name="dei:EntityCentralIndexKey" id="Tc_BPi0QZgN-0a3YAKoRrdTtQ_2_1">0001650664</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" name="dei:AmendmentFlag" id="Tc_aG27fwsPckSYdNWwL3l2Ag_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="edit-20200109.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-09</xbrli:startDate><xbrli:endDate>2020-01-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:15.52pt;"><a id="_af4273c9_8fa2_4af3_8023_23a538ea4a1b"></a><p style="font-family:'Times New Roman';font-size:12pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:18pt;font-weight:bold;text-align:center;margin:0pt 0pt 3pt 0pt;">FORM&#160;<ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" name="dei:DocumentType" id="Narr_fq7_iZA5iUOTByOiKvpLGA">8-K</ix:nonNumeric></p><div style="font-family:'Times New Roman';font-size:13.5pt;margin-bottom:9pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CURRENT REPORT<br />Pursuant to Section&#160;13 or 15(d)<br />of The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;">Date of Report (Date of earliest event reported): </span><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_CnA79LIDPk-dMxCIG2zf3g"><span style="font-size:10pt;">January 9, 2020</span></ix:nonNumeric></p><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:18pt;font-weight:bold;text-align:center;margin:0pt 0pt 3pt 0pt;"><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" name="dei:EntityRegistrantName" id="Narr_qvd0dfiiAEORO7MNoZDuyQ">Editas Medicine, Inc.</ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">(Exact Name of Registrant as Specified in its Charter)</p><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_3adfa712_def6_4d30_8ee6_bcc325048289"></a><a id="Tc_szUv65aHZ0igB47dcHT1aQ_2_0"></a><a id="Tc_io2LnCStRUSvNUi02xEwaw_2_1"></a><a id="Tc_cYfH0jtaFUiGnhJ3EQkjQQ_2_2"></a></div></div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:26.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_0-8IEwoS7Uyw-totDw8i2g_1_0"><b style="font-size:10pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:26.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" name="dei:EntityFileNumber" id="Tc_IkER2ehafUic0-Mwsc6m8g_1_1"><b style="font-size:10pt;font-weight:bold;">001-37687</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" name="dei:EntityTaxIdentificationNumber" id="Tc_lheJF9CpJ0qH2v4QxG3wFA_1_2"><b style="font-size:10pt;font-weight:bold;">46-4097528</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">(State or Other Jurisdiction of Incorporation)</p></td><td style="vertical-align:top;width:26.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:top;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9d6c3cd2_3df0_4c12_91a0_c59cf0e71d49"></a><a id="Tc_od7_YiD8W0yfTi6R_mbCBQ_1_0"></a><a id="Tc_h9yxqy46mUii5a1OD8h82w_2_0"></a><a id="Tc_XWnw71OKl0awRIedN_jnBg_2_1"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:45.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" name="dei:EntityAddressAddressLine1" id="Narr_4ezy2fOym02-8wCxnFMjrw"><b style="font-size:10pt;font-weight:bold;">11 Hurley Street</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;"><br /></b><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" name="dei:EntityAddressCityOrTown" id="Narr_CMxV5LBqsU-QoLLCfWyW-A"><b style="font-size:10pt;font-weight:bold;">Cambridge</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_0kFWuUaGI0u9f0PQ7YkspA"><b style="font-size:10pt;font-weight:bold;">Massachusetts</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:45.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" name="dei:EntityAddressPostalZipCode" id="Tc_Uwh1mfcGJUGTGSfgXN-6UQ_1_1"><b style="font-size:10pt;font-weight:bold;">02141</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:54.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:top;width:45.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;">Registrant&#8217;s telephone number, including area code:&#160;</span><b style="font-size:10pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" name="dei:CityAreaCode" id="Narr_L1EU4vdS80O70IUGuKc4hg"><b style="font-size:10pt;font-weight:bold;">617</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">)&#160;</b><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" name="dei:LocalPhoneNumber" id="Narr_hCt7Hbhxc0qaHbEzhT4U-g"><b style="font-size:10pt;font-weight:bold;">401-9000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction&#160;A.2. below):</p><a id="_03954c9c_0f6f_44ac_b87d_250785e27b4e"></a><a id="Tc_fO_TLnxWGEGGMSjjhJtajg_1_1"></a><a id="Tc_kux-PnO14EidNtZfyJxMMw_3_1"></a><a id="Tc_DwB3zTfDV0G3_6djEUsFHA_5_1"></a><a id="Tc_KKtS9OJzUE-P_PB5p7Uvrw_7_1"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_xvsJOObYe0S79KBlyrnW4g_1_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17&#160;CFR&#160;230.425)</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_7zcOh9w9JUOP-qis_PWBjA_3_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17&#160;CFR&#160;240.14a-12)</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_G8923Rmef0-Tczezja3NNA_5_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17&#160;CFR&#160;240.14d-2(b))</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_njhAmpchH06g19C_bZU7_A_7_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17&#160;CFR&#160;240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><a id="_dcb8c928_e46c_434f_a26a_0d9cf6b41806"></a><a id="Tc_1AIe9RGltESn9ncASO6D9w_1_0"></a><a id="Tc_RXu6Hxh6n0iwFxTfEN9-aA_1_1"></a><a id="Tc_pPovP5itCk6ZzNpUNTo7eQ_1_2"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:11.8pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr style="height:17.65pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" name="dei:Security12bTitle" id="Tc_TRKOlAby7EC_0Fxg5QhrwA_2_0"><span style="font-size:8pt;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" name="dei:TradingSymbol" id="Tc_hIyPra2ya0SZX7VaDWGyeg_2_1"><span style="font-size:8pt;">EDIT</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_RgKCg4DNrUKBMrQsvGZn0w_2_2"><span style="font-size:8pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-<span style="white-space:pre-wrap;">2 of this chapter).    </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:36pt;margin:6pt 0pt 6pt 0pt;"><span style="font-size:10pt;">Emerging growth company&#160;</span><ix:nonNumeric contextRef="Duration_1_9_2020_To_1_9_2020_hl3RzSZ5WUaCTbJog6Yjkg" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_tb8JFbj5OU-nsBrue9CNJQ"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span>&#160;</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;padding-bottom:1pt;padding-top:1pt;text-indent:36pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:3pt;margin:0pt;">&#160;</p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_43e86f6c_57c3_4cb2_a50f_40384e880e44"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;padding-bottom:12pt;padding-left:72pt;text-indent:-72pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;5.02. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</b></p><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">On January 9, 2020, the board of directors (the &#8220;Board&#8221;) of Editas Medicine, Inc. (the &#8220;Company&#8221; or &#8220;Editas&#8221;) appointed Michelle Robertson as the Chief Financial Officer, principal accounting officer, principal financial officer, Treasurer and Assistant Secretary of the Company, effective immediately.  Ms. Robertson succeeded Eric Ek, whose service as the Company&#8217;s interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer ended upon Ms. Robertson&#8217;s appointment.</span></p><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">Ms. Robertson, age 53, previously served as the Chief Financial Officer of Momenta Pharmaceuticals, Inc. (&#8220;Momenta&#8221;), a publicly traded biotechnology company, from October 2018 until January 8, 2020, and as Vice President, Financial Planning and Analysis of Momenta from May 2017 to October 2018. Prior to joining Momenta, Ms. Robertson was Vice President, Oncology Finance for Baxalta, Inc., a biopharmaceutical company, following its spin-off from Baxter International, from 2015 to 2016. From 2012 to 2015, Ms. Robertson served as Head of Financial Planning and Analysis and Operations Excellence at Ironwood Pharmaceuticals, Inc., and prior to that, held various leadership positions in the Oncology and Biosurgery divisions of Finance and Commercial Operations at Genzyme Corporation (now Sanofi Genzyme), a biotechnology company. Ms. Robertson received her B.S. in Finance and A.S. in Accounting and Management from Bentley University.</p><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In connection with her appointment, the Company entered into an employment offer letter with Ms. Robertson, dated December 3, 2019 (the &#8220;Offer Letter&#8221;). The Offer Letter provides for an annual base salary of $400,000, an annual target bonus equal to 40% of Ms. Robertson&#8217;s base salary and a one-time sign-on bonus of $140,000, subject in the case of the sign-on bonus to repayment by Ms. Robertson to the Company if she leaves the Company other than for good reason or is terminated for cause (each as defined in the Company&#8217;s Severance Benefits Plan, as amended (the &#8220;Severance Plan&#8221;)) within the first year of her employment.  In addition, the Board granted Ms. Robertson (i) an option to purchase 120,000 shares of the Company&#8217;s common stock, which is scheduled to vest as to 25% of the shares underlying the option on January 9, 2021 and an additional 2.0833% of the shares underlying the option at the end of each successive month following such date (the &#8220;Option&#8221;) until January 9, 2024, and (ii) a restricted stock unit award for 20,000 shares of the Company&#8217;s common stock, which is scheduled to vest as to one-fourth of the shares on each anniversary of January 9, 2020 until January 9, 2024, in each case subject to her continued service. The Option has an exercise price equal to $30.65 per share.  Ms. Robertson is also entitled to severance benefits in accordance with the Severance Plan.</span></p><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><a id="_e719e7ac_bbc8_4f1e_beaf_19bb5a150fe9"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">EDITAS MEDICINE, INC.</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">January 10, 2020</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:43.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">/s/ Cynthia Collins</p></td></tr><tr><td style="vertical-align:bottom;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:43.25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cynthia Collins<br />Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "edit-20200109x8k01a92cf.htm", "description": "8-K", "secsgml_size_bytes": 31590}]
{"company-data": {"conformed-name": "Editas Medicine, Inc.", "cik": "0001650664", "assigned-sic": "2836", "irs-number": "464097528", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-37687", "film-number": "20521070"}, "business-address": {"street1": "11 HURLEY ST.", "city": "CAMBRIDGE", "state": "MA", "zip": "02141", "phone": "617-401-9000"}, "mail-address": {"street1": "11 HURLEY ST.", "city": "CAMBRIDGE", "state": "MA", "zip": "02141"}}
​
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 9, 2020
Editas Medicine, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware
001-37687
46-4097528
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
​
11 Hurley Street
Cambridge
,
Massachusetts
02141
(Address of Principal Executive Offices)
(Zip Code)
​
Registrant's telephone number, including area code:
(
617
)
401-9000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
​
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
EDIT
The Nasdaq Stock Market LLC
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-
2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
​
​
Item 5.02.            Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On January 9, 2020, the board of directors (the "Board") of Editas Medicine, Inc. (the "Company" or "Editas") appointed Michelle Robertson as the Chief Financial Officer, principal accounting officer, principal financial officer, Treasurer and Assistant Secretary of the Company, effective immediately.  Ms. Robertson succeeded Eric Ek, whose service as the Company's interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer ended upon Ms. Robertson's appointment.
Ms. Robertson, age 53, previously served as the Chief Financial Officer of Momenta Pharmaceuticals, Inc. ("Momenta"), a publicly traded biotechnology company, from October 2018 until January 8, 2020, and as Vice President, Financial Planning and Analysis of Momenta from May 2017 to October 2018. Prior to joining Momenta, Ms. Robertson was Vice President, Oncology Finance for Baxalta, Inc., a biopharmaceutical company, following its spin-off from Baxter International, from 2015 to 2016. From 2012 to 2015, Ms. Robertson served as Head of Financial Planning and Analysis and Operations Excellence at Ironwood Pharmaceuticals, Inc., and prior to that, held various leadership positions in the Oncology and Biosurgery divisions of Finance and Commercial Operations at Genzyme Corporation (now Sanofi Genzyme), a biotechnology company. Ms. Robertson received her B.S. in Finance and A.S. in Accounting and Management from Bentley University.
In connection with her appointment, the Company entered into an employment offer letter with Ms. Robertson, dated December 3, 2019 (the "Offer Letter"). The Offer Letter provides for an annual base salary of $400,000, an annual target bonus equal to 40% of Ms. Robertson's base salary and a one-time sign-on bonus of $140,000, subject in the case of the sign-on bonus to repayment by Ms. Robertson to the Company if she leaves the Company other than for good reason or is terminated for cause (each as defined in the Company's Severance Benefits Plan, as amended (the "Severance Plan")) within the first year of her employment.  In addition, the Board granted Ms. Robertson (i) an option to purchase 120,000 shares of the Company's common stock, which is scheduled to vest as to 25% of the shares underlying the option on January 9, 2021 and an additional 2.0833% of the shares underlying the option at the end of each successive month following such date (the "Option") until January 9, 2024, and (ii) a restricted stock unit award for 20,000 shares of the Company's common stock, which is scheduled to vest as to one-fourth of the shares on each anniversary of January 9, 2020 until January 9, 2024, in each case subject to her continued service. The Option has an exercise price equal to $30.65 per share.  Ms. Robertson is also entitled to severance benefits in accordance with the Severance Plan.
​
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EDITAS MEDICINE, INC.
​
Date:
January 10, 2020
​
By:
/s/ Cynthia Collins
​
Cynthia Collins
Chief Executive Officer
​
​
​